GAUDIUMIVF
Gaudium IVF and Women Health share price & financials
- Price
- ₹143.78
- Market cap
- ₹811 Cr
- Sector
- Healthcare
- Calls analysed
- 2
Gaudium IVF and Women Health Limited Q1 FY27
What went well
- Revenue for Q1 FY27 grew by 9.1% year-on-year to ₹19.4 crores.
- Clinical pregnancy success rate grew to 62% in the first attempt, with a cumulative pregnancy rate of 85%.
- AI-led embryology tools (SiD and ERICA) integrated, showing an approximately 8% improvement in first attempt outcomes.
What to watch
- Reported EBITDA for Q1 FY27 moderated by 52.96% year-on-year to ₹2.4 crores.
- Reported EBITDA margin contracted by 1,651 bps to 12.5% in Q1 FY27, down from 29% in Q1 FY26.
What Gaudium IVF and Women Health Limited does
Gaudium IVF and Women Health Limited runs fertility clinics under the Gaudium IVF brand, delivering IVF treatment along with hospital and pharmacy services through a hub-and-spoke network of comprehensive-care hubs and smaller spoke centres across India. Patients move through a structured, SOP-driven pathway — registration, ovulation induction, ovum pick-up, embryo transfer, and post-transfer care — supported by embryology labs, andrology labs, surgical suites and cryo-storage facilities at each hub. The company also serves international patients, including from the Middle East, UK, Africa, Australia, New Zealand, Canada and Indonesia, and has deployed proprietary AI tools (SiD for sperm selection, ERICA for embryo ranking) to support clinical decision-making.
Segments
- IVF Treatment
- Hospital
- Pharmacy
- Hubs (comprehensive care centres)
- 7
- Spokes (extended access centres)
- 28
- States with presence
- 9
- Total beds across hubs
- 51 (across 7 hubs)
- Operation theatres
- 7 (one per hub)
- Ovum Pick Up (OPU) procedures
- 2,255
Guidance record · Q1 FY27
what the last two calls moved 12 tracked 0 delivered 2 missed 10 open- New International Spokes went quiet said Q4 FY26 Promised: 3 international spokes (Paris, Nigeria, Sydney) to be added this quarter Q1 FY27: Management mentioned they are 'establishing' three international spokes in Paris, Nigeria, and Sydney, but did not confirm if they were added in Q1 FY27 as originally promised.
- New IVF Hubs (Total) on track said Q4 FY26 Promised: 19 new IVF hubs planned under IPO use of proceeds Q1 FY27: Reiterated the plan for 19 hubs (10 in FY27, 8 in FY28, 1 in FY29) and made the first one (South Extension) operational on July 16, 2026.
All 12 tracked — every revision, and every one management stopped mentioning.
Open the guidance ledgerQuarterly results
Q1 FY27: revenue up 9.1%, net profit down 42.0% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|
| Revenue | 14 | 27 | 18 | 32 | 25 +70% | 30 +13% | 19 +9% |
| EBITDA | 6 | 9 | 5 | 14 | 7 +16% | 12 +40% | 2 −53% |
| Net profit | 3 | 6 | 3 | 9 | 4 +7% | 8 +29% | 2 −42% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance +46.7% YTD
YTD: ₹80.26 on 27 Feb 2026 → ₹117.75. High ₹158.16 (22 Jul 2026), low ₹70.67 (23 Mar 2026).
How the price took the results
close before → close after
- Q4 FY26
- +0.2%
- 29 May
The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.
Financials, as filed
| Year ending | FY26 |
|---|---|
| Revenue | ₹104 Cr |
| Operating profit | ₹38 Cr |
| Operating margin | 36.1% |
| Interest | ₹4 Cr |
| Depreciation | ₹2 Cr |
| Net profit | ₹24 Cr |
| Net margin | 23.4% |
| Cash from operations | ₹7 Cr |
| Free cash flow | ₹5 Cr |
| ROCE | 29.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Equity capital | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹31 Cr | ₹36 Cr |
| Reserves | ₹8 Cr | ₹22 Cr | ₹26 Cr | ₹28 Cr | ₹116 Cr |
| Borrowings | ₹6 Cr | ₹12 Cr | ₹17 Cr | ₹24 Cr | ₹25 Cr |
| Other liabilities | ₹3 Cr | ₹2 Cr | ₹7 Cr | ₹24 Cr | ₹16 Cr |
| Total liabilities | ₹18 Cr | ₹37 Cr | ₹51 Cr | ₹107 Cr | ₹193 Cr |
| Fixed assets | ₹4 Cr | ₹18 Cr | ₹19 Cr | ₹30 Cr | ₹30 Cr |
| Capital work in progress | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹5 Cr | ₹5 Cr |
| Other assets | ₹14 Cr | ₹18 Cr | ₹32 Cr | ₹72 Cr | ₹158 Cr |
| Total assets | ₹18 Cr | ₹37 Cr | ₹51 Cr | ₹107 Cr | ₹193 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
Since Mar 2026, the public added +4.08 pp while FIIs trimmed −3.69 pp. The shareholder count grew 10% to 21,910.
- Promoters
- 71.3%
- FIIs
- 3.0%
- DIIs
- 2.2%
- Public
- 23.5%
Since Mar 2026
- Public +4.08 pp
- FIIs −3.69 pp
- DIIs −0.41 pp
Who bought this quarter
since Mar 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Gdn Ventures Llp newly disclosed 4.26% held
The same filing shows 2 holders trimming and 3 off the list — both are in the register beside this.
Who is on the register
Named in the Jun 2026 filing
Every holder of Gaudium IVF and Women Health Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Manika Khanna | 70.73% | unchanged |
| Gdn Ventures Llp | 4.26% | newly disclosed |
| Mukul Mahavir Agrawal | 3.43% | unchanged |
| Sanshi Fund-I AIF | 1.79% | −0.38 pp |
| Meru Investment Fund Pcc-Cell 1 FPI fund | 1.46% | −1.56 pp |
| Kishan Gopal Mohta | 1.28% | unchanged |
| Peeyush Khanna | 0.30% | unchanged |
| Vishad Khanna | 0.26% | unchanged |
| Gautam Anand | 0.01% | unchanged |
| Rajinder Kumar Anand | 0.00% | unchanged |
| Malini Anand | 0.00% | unchanged |
| Shobhini Khanna | 0.00% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
What the price assumes
- Growth the price implies
- 24.8% a year
- for 7 years, fading to 4%
- It has actually compounded at
- Not enough history
- The gap
- —
- between what it did and what it must do
All earnings calls (2)
Read the Q1 FY27 call →Learn to analyse Gaudium IVF and Women Health Limited
Guides on how to read this kind of business and the numbers that matter.